Overview

The Effect of LINAGLIPTIN on Inflammation, Oxidative Stress and Insulin Resistance in Obese Type 2 Diabetes Subjects

Status:
Unknown status

Trial end date:
2018-05-01

Target enrollment:

Participant gender:

Summary

This is a single center, prospective randomized double blind, parallel and placebo controlled study to evaluate oxidative stress and inflammation before and after treatment with linagliptin for 12 weeks. We will also, testing whether Linagliptin is an insulin sensitizer.

Phase:

Phase 4

Details

Lead Sponsor:

University at Buffalo

Collaborator:

Kaleida Health

Treatments:

Linagliptin